The cytotoxic effects of single-stranded telomere mimics on OMA-BL1 cells

Experimental Cell Research

Volumn 252, Issue 1, 1999, Pages 41-49

  Page, Todd J ^a,b   Mata, John E ^a,c   Bridge, Julia A ^a   Siebler, Justin C ^a   Neff, James R ^a   Iversen, Patrick L ^a,b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c AVI BIOPHARMA INC   (United States)

Author keywords

Drug development; Lymphoma; Phosphorothioate oligonucleotide; Sarcoma; Telomerase inhibitor; Telomere

Indexed keywords

RIBONUCLEOPROTEIN; TELOMERASE;

ANIMAL CELL; ARTICLE; CELL IMMORTALIZATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA FLANKING REGION; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROGEN BOND; MOUSE; NONHUMAN; PRIORITY JOURNAL; TELOMERE;

EID: 0033544006     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.1999.4613     Document Type: Article

References (44)

1. Lundblad V., Szostak J. W. A mutant with a defect in telomere elongation leads to senescence in yeast. Cell. 57:1989;633-643.
2. Morin G. B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 59:1989;521-529.
3. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W. Specific association of human telomerase activity with immortal cells and cancer [see comments]. Science. 266:1994;2011-2015.
4. Blasco M. A., Rizen M., Greider C. W., Hanahan D. Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nature Genet. 12:1996;200-204.
5. Counter C. M., Hirte H. W., Bacchetti S., Harley C. B. Telomerase activity in human ovarian carcinoma [see comments]. Proc. Natl. Acad. Sci. USA. 91:1994;2900-2904.
6. Hiyama K., Hirai Y., Kyoizumi S., Akiyama M., Hiyama E., Piatyszek M. A., Shay J. W., Ishioka S., Yamakido M. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155:1995;3711-3715.
7. Ueda M., Ouhtit A., Bito T., Nakazawa K., Lubbe J., Ichihashi M., Yamasaki H., Nakazawa H. Evidence for UV-associated activation of telomerase in human skin. Cancer Res. 57:1997;370-374.
8. Klingelhutz A. J., Foster S. A., McDougall J. K. Telomerase activation by the E6 gene product of human papillomavirus type 16. Nature. 380:1996;79-82.
9. Bodnar A. G., Ouellette M., Frolkis M., Holt S. E., Chiu C. P., Morin G. B., Harley C. B., Shay J. W., Lichtsteiner S., Wright W. E. Extension of life-span by introduction of telomerase into normal human cells [see comments]. Science. 279:1998;349-352.
10. Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8:1998;279-282.
11. Kanazawa Y., Ohkawa K., Ueda K., Mita E., Takehara T., Sasaki Y., Kasahara A., Hayashi N. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem. Biophys. Res. Commun. 225:1996;570-576.
12. Norton J. C., Piatyszek M. A., Wright W. E., Shay J. W., Corey D. R. Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotechnol. 14:1998;615-619.
13. Sharma H. W., Maltese J. Y., Zhu X., Kaiser H. E., Narayanan R. Telomeres, telomerase and cancer: Is the magic bullet real. Anticancer Res. 16:1996;511-515.
14. Sharma S., Raymond E., Soda H., Sun D., Hilsenbeck S. G., Sharma A., Izbicka E., Windle B., Von Hoff D. D. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann. Oncol. 8:1997;1063-1074.
15. Blasco M. A., Lee H. W., Hande M. P., Samper E., Lansdorp P. M., DePinho R. A., Greider C. W. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA [see comments]. Cell. 91:1997;25-34.
16. Mata J. E., Joshi S. S., Palen B., Pirruccello S. J., Jackson J. D., Elias N., Page T. J., Medlin K. L., Iversen P. L. A hexameric phosphorothioate oligonucleotide telomerase inhibitor arrests growth of Burkitt's lymphoma cells in vitro and in vivo. Toxicol. Appl. Pharmacol. 144:1997;189-197.
17. Joshi S. S., Deboer J. M., Standjord S. J., Pirrucello S. J., Sanger W. G., Weisenberger D. D., Sharp J. G. Characterization of newly established human Burkitt's lymphoma cell line, OMA-BL1. Int. J. Cancer. 47:1991;643-648.
18. Birnboim H. C., Mitchel R. E. J. Prevention of G:C pairing in mouse DNA by complete blocking of guanine residues with glyoxal. Biochim. Biophys. Acta. 517:1978;296-307.
19. Broude N. E., Budowsky E. I. The reaction of glyoxal nucleic acid components. III. Kinetics of the reaction with monomers. Biochim. Biophys. Acta. 254:1971;380-388.
20. Watanabe W., Konno K., Ijichi K., Inoue H., Yokota T., Shigeta S. MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents. J. Virol. Methods. 48:1994;257-265.
21. Zahler A. M., Williamson J. R., Cech T. R., Prescott D. M. Inhibition of telomerase by G-quartet DNA structures. Nature. 350:1991;718-720.
22. Parkinson E. K. Do telomerase antagonists represent a novel anti-cancer strategy? [Editorial]. Br. J. Cancer. 73:1996;1-4.
23. Burger A. M., Double J. A., Newell D. R. Inhibition of telomerase activity by cisplatin in human testicular cancer cells. Eur. J. Cancer. 33:1997;638-644.
24. Fletcher T. M., Salazar M., Chen S. F. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates. Biochemistry. 35:1996;15611-15617.
25. Ku W. C., Cheng A. J., Wang T. C. Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture. Biochem. Biophys. Res. Commun. 241:1997;730-736.
26. Sun D., Thompson B., Cathers B. E., Salazar M., Kerwin S. M., Trent J. O., Jenkins T. C., Neidle S., Hurley L. H. Inhibition of human telomerase by a G-quadruplex-interactive compound. J. Med. Chem. 40:1997;2113-2116.
27. Melana S. M., Holland J. F., Pogo B. G. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. 4:1998;693-696.
28. Rhyu M. S. Telomeres, telomerase, and immortality [see comments]. J. Natl. Cancer Inst. 87:1995;884-894.
29. Gualberto A., Patrick R. M., Walsh K. Nucleic acid specificity of a vertebrate telomere-binding protein: evidence for G:G base pair recognition at the core-binding site. Genes Dev. 6:1992;815-824.
30. Williamson J. R., Raghuraman M. K., Cech T. R. Monovalent cation-induced structure of telomeric DNA: The G-quartet model. Cell. 59:1989;871-880.
31. Fang G., Cech T. R. Characterization of a G-quartet formation reaction promoted by the beta-subunit of the Oxytricha telomere-binding protein. Cell. 74:1993;875-885.
32. Veselkov A. G., Malkov V. A., Frank-Kamenetskii M. D., Dobrynin V. N. Triplex model of chromosome ends. Nature. 364:1993;496.
33. Walsh K., Gualberto A. MyoD binds to the guanine tetrad nucleic acid structure. J. Biol. Chem. 267:1992;13714-13718.
34. Liu Z., Frantz J. D., Gilbert W., Tye B. K. Identification and characterization of a nuclease activity specific for G4 tetastranded DNA. Proc. Natl. Acad. Sci. USA. 90:1993;3157-3161.
35. Henderson E. R., Hardin C. C., Walk S. K., Tinoco I. Jr., Blackburn E. H. Telomeric DNA oligonucleotides form novel intramolecular structures containing guanine-guanine base pairs. Cell. 51:1987;899-908.
36. Sharma H. W., Hsiao R., Narayanan R. Telomerase as a potential molecular target to study G-quartet phosphorothioates. Antisense Nucleic Acid Drug Dev. 6:1996;3-7.
37. Burgess T. L., Fisher E. F., Ross S. L., Bready J. V., Qian Y. X., Bayewitch L. A., Cohen A. M., Herrera C. J., Hu S. S., Kramer T. B. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc. Natl. Acad. Sci. USA. 92:1995;4051-4055.
38. Pirrucello S. J., Perry G. A., Bock P. J., Lang M. S., Noel S. M., Zon G., Iversen P. L. HIV-1 rev antisense phosphorothioate oligonucleotide binding to human mononuclear cells is cell type specific and inducible. Antisense Res. Dev. 4:1994;285-289.
39. Baeuerle P. A., Rupec R. A., Pahl H. L. Reactive oxygen intermediates as second messengers of a general pathogen response. Pathol. Biol. 44:1996;29-35.
40. Driggers W. J., Holmquist G. P., LeDoux S. P., Wilson G. L. Mapping frequencies of endogenous oxidative damage and the kinetic response to oxidative stress in a region of rat mtDNA. Nucleic Acids Res. 25:1997;4362-4369.
41. Guidarelli A., Brambilla L., Rota C., Tomasi A., Cattabeni F., Cantoni O. The respiratory-chain poison antimycin A promotes the formation of DNA single-strand breaks and reduces toxicity in U937 cells exposed to t-butylhydroperoxide. Biochem. J. 317:1996;371-375.
42. Spencer J. P. E., Jenner A., Aruoma O. I., Cross C. E., Wu R., Halliwell B. Oxidative DNA damage in human respiratory tract epithelial cells: Time course in relation to DNA strand breakage. Biochem. Biophys. Res. Commun. 224:1996;17-22.
43. Collins A. R., Dusinska M., Gedik C. M., Stetina R. Oxidative damage to DNA: Do we have a reliable biomarker. Environ. Health Perspect. Suppl. 104:1996;465-469.
44. Petersen S., Saretzki G., von Zqlinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp. Cell Res. 239:1998;152-160.